About: Turoctocog alfa

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Turoctocog alfa (trade name NovoEight) is a recombinant antihemophilic factor VIII used for the treatment of and prophylaxis of bleeding patients with haemophilia A. It is marketed by Novo Nordisk. It was approved in the United States, the European Union, and Japan in 2013.

Property	Value
dbo:abstract	Turoctocog alfa (trade name NovoEight) is a recombinant antihemophilic factor VIII used for the treatment of and prophylaxis of bleeding patients with haemophilia A. It is marketed by Novo Nordisk. It was approved in the United States, the European Union, and Japan in 2013. (en)
dbo:alternativeName	NovoEight, Esperoct (en)
dbo:casNumber	1192451-26-5
dbo:chEMBL	2108175
dbo:drugbank	DB09109
dbo:fdaUniiCode	969NZA3X9T P89DR4NY54
dbo:kegg	D10227 D10758
dbo:wikiPageExternalLink	https://druginfo.nlm.nih.gov/drugportal/name/turoctocog%20alfa https://druginfo.nlm.nih.gov/drugportal/name/turoctocog%20alfa%20pegol
dbo:wikiPageID	41872607 (xsd:integer)
dbo:wikiPageLength	11268 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1095798149 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Von_Willebrand_disease dbr:Intravenous_therapy dbr:NovoSeven dbc:Recombinant_proteins dbr:Chinese_hamster_ovary_cell dbr:Haemophilia_A dbr:Novo_Nordisk dbr:Thrombin dbr:Factor_VIII dbr:Factor_X dbr:Pyrexia dbr:Antihemophilic_factor
dbp:atcPrefix	B02 (en)
dbp:atcSuffix	BD02 (en)
dbp:c	7480 (xsd:integer)
dbp:casNumber	1192451 (xsd:integer)
dbp:chembl	2108175 (xsd:integer)
dbp:chemspiderid	none (en)
dbp:dailymedid	NovoEight (en)
dbp:drugbank	DB09109 (en)
dbp:h	11379 (xsd:integer)
dbp:kegg	D10227 (en) D10758 (en)
dbp:legalAu	Exempt (en)
dbp:legalCa	Rx-only / Schedule D (en)
dbp:legalEu	Rx-only (en)
dbp:legalStatus	Rx-only (en)
dbp:legalUk	POM (en)
dbp:legalUs	Rx-only (en)
dbp:licenceEu	yes (en)
dbp:licenceUs	NovoEight (en)
dbp:n	1999 (xsd:integer)
dbp:o	2194 (xsd:integer)
dbp:pregnancyAu	B2 (en)
dbp:routesOfAdministration	dbr:Intravenous_therapy
dbp:s	68 (xsd:integer)
dbp:synonyms	recombinant antihemophilic factor (en)
dbp:tradename	NovoEight, Esperoct (en)
dbp:unii	969 (xsd:integer) P89DR4NY54 (en)
dbp:wikiPageUsesTemplate	dbt:Cite_web dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Use_dmy_dates dbt:Drugs.com dbt:Antihemorrhagics
dcterms:subject	dbc:Recombinant_proteins
gold:hypernym	dbr:VIII
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:Agent114778436 yago:CausalAgent100007347 yago:Drug103247620 yago:Matter100020827 yago:PhysicalEntity100001930 dbo:Drug yago:Substance100020090
rdfs:comment	Turoctocog alfa (trade name NovoEight) is a recombinant antihemophilic factor VIII used for the treatment of and prophylaxis of bleeding patients with haemophilia A. It is marketed by Novo Nordisk. It was approved in the United States, the European Union, and Japan in 2013. (en)
rdfs:label	Turoctocog alfa (en)
owl:sameAs	freebase:Turoctocog alfa wikidata:Turoctocog alfa https://global.dbpedia.org/id/25gjc
prov:wasDerivedFrom	wikipedia-en:Turoctocog_alfa?oldid=1095798149&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Turoctocog_alfa
is dbo:wikiPageRedirects of	dbr:NovoEight dbr:Esperoct dbr:Turoctocog dbr:Turoctocog_alfa_pegol
is dbo:wikiPageWikiLink of	dbr:NovoEight dbr:Esperoct dbr:Factor_VIII_(medication) dbr:List_of_drugs:_Trj–Tz dbr:Turoctocog dbr:Turoctocog_alfa_pegol
is foaf:primaryTopic of	wikipedia-en:Turoctocog_alfa